Gastroenterology & Endoscopy News

Gastroenterology & Endoscopy News Monthly newspaper for gastroenterologists, colorectal surgeons, hepatologists, PAs and NPs.

09/16/2026

Advanced IBD therapies are evolving rapidly—but getting them to patients is still a major hurdle.

New data highlights how prior authorization denials are not just administrative delays… they can actively reshape the course of care, from treatment timing to disease control.

One emerging solution? A dedicated, structured APP + PharmD workflow that significantly improves efficiency and consistency in the appeal process.

What happens when specialized teams take on the “hidden workload” of advanced IBD care?

Read more: https://www.gastroendonews.com/a/tToBAA/f

How does the U.S. actually pay for healthcare?Part 2 of a healthcare-financing series from Klaus Mergener, MD, PhD, MBA,...
09/15/2026

How does the U.S. actually pay for healthcare?

Part 2 of a healthcare-financing series from Klaus Mergener, MD, PhD, MBA, MASGE, breaks down the patchwork of employer, ACA marketplace, Medicare, and Medicaid coverage that patients move through based on age, job, income, and state.

National health spending reached about $5.3 trillion in 2024 — nearly 18% of GDP, split across private insurance, Medicare, Medicaid, and out-of-pocket costs.

What would it take to simplify this system?

Read more: https://f.mtr.cool/67m2tdw3rw

🤖 Sitting in a chair, controlling the scope with a console instead of your hands — that's the pitch behind a new robotic...
09/14/2026

🤖 Sitting in a chair, controlling the scope with a console instead of your hands — that's the pitch behind a new robotic colonoscopy system.

In a first-in-human study of 50 patients presented at DDW 2026, the Triton system (Neptune Medical) achieved 100% cecal intubation and completed 77 polypectomies, with no major adverse events reported.

✔️ 100% cecal intubation across all patients
✔️ Perceived workload score: 36 (robotic) vs. 105 (manual)

Independent reviewers note the study population skewed younger. Will robotic platforms prove themselves in older, more diverse patients — and improve outcomes, not just ergonomics?

Read more: https://f.mtr.cool/4k945bive1

09/12/2026

When treating inflammatory bowel disease, cancer risk is often framed as a medication problem—but is that the full story?

New expert discussions suggest a more complex balance: distinguishing cancer risk driven by IBD itself from risks potentially associated with therapy—and recognizing when undertreatment may actually be the greater threat.

The real challenge may not be choosing between risk and safety, but understanding where each risk truly comes from.

Read more: https://www.gastroendonews.com/a/cjkBAA/f

09/11/2026

What does “remission” in IBD really mean—and who gets to define it?

New survey data highlights a striking gap between how patients and clinicians interpret remission: symptom relief vs objective inflammation control.

At the same time, longer-term data from a key Crohn’s disease trial suggests sustained outcomes may be more achievable with newer therapies than earlier biologic generations.

The bigger question: are we aligned on what success actually looks like in IBD care?

Read more: https://www.gastroendonews.com/a/tDoBAA/f

09/11/2026

🔮 The future of endoscopy is closer than you think.

Imagine AI-assisted imaging, robotic endoscopes, hyperspectral tissue analysis, voice-controlled procedure rooms, and even "cobots" helping streamline workflow.

Experts shared a glimpse into the endoscopy suite of tomorrow and the innovations that could redefine GI care in the years ahead.

Discover what's on the horizon: https://www.gastroendonews.com/a/mjsBAA/f

09/11/2026

Acute pancreatitis remains one of gastroenterology’s most common—and debated—clinical challenges.

At a recent GI symposium, experts reviewed emerging evidence across several controversial areas of management.

Several themes are becoming clearer:
• Lactated Ringer’s solution may outperform saline
• Moderate hydration appears safer than aggressive resuscitation
+ more

At the same time, many questions remain unresolved—particularly around drainage timing and post-pancreatitis diabetes risk.

Read more: https://www.gastroendonews.com/a/qjoBAA/f

09/10/2026

Acute pancreatitis treatment is still full of “it depends.”

Even things like IV fluids, antibiotics, pain control, and when to start feeding patients are still being debated by experts.

New research is helping clarify some decisions—but not all of them.

Here’s what’s currently changing in how clinicians think about care 👇
https://www.gastroendonews.com/a/qjoBAA/f

It’s time to start seeing C. diff differently.From evolving diagnostics to shifting resistance patterns and a rapidly ch...
09/10/2026

It’s time to start seeing C. diff differently.

From evolving diagnostics to shifting resistance patterns and a rapidly changing treatment landscape, experts at IDWeek 2025 are urging clinicians to rethink how they identify and manage Clostridioides difficile infection.

Are we over-testing, under-optimizing treatment—or both?

Read more: https://www.gastroendonews.com/a/8DsBAA/f

09/09/2026

Are we entering a new era of liver fibrosis monitoring?

Emerging evidence supports expanding the role of noninvasive liver disease assessments (NILDAs), particularly the Enhanced Liver Fibrosis (ELF) test, in risk stratification for patients with MASLD/MASH.

Recent pooled analyses suggest that changes over time in ELF scores may help identify patients at highest risk for liver-related events—raising important questions about how we define meaningful endpoints in both clinical practice and trials.

More data may be reshaping how we think about “progression.”: https://www.gastroendonews.com/a/qToBAA/f

Address

New York, NY

Telephone

+12129575300

Website

Alerts

Be the first to know and let us send you an email when Gastroenterology & Endoscopy News posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category